Biotronik and Endosense launch TactiCath Quartz catheter

Biotronik and Endosense have announced the CE Mark approval and first clinical use of their new TactiCath Quartz catheter device.

The force-sensing ablation catheter is a third-generation device that offers benefits such as improved sensitivity and precision, a small footprint, a user-friendly interface and connectivity with other lab equipment.

It has been used for the first time by renowned physicians based at three centres across Europe: the University Hospital of Geneva, the Heart and Diabetes Center in Bad Oeynhausen and the University Hospital Grosshadern in Munich.

This latest TactiCath device is approved for the treatment of atrial fibrillation and supraventricular tachycardia.

Dr Dipen Shah from the University Hospital of Geneva said: "As a long-time user of the TactiCath, I find the Quartz generation to be another significant improvement in the field."

Last month, the company announced positive data from its 4Ever clinical study, which assessed the efficacy of the Pulsar stent system among 120 superficial femoral artery patients.